Open Accessbc1‐2 and MIB‐1 Labeling Indexes in Cats with Lymphoma
Author(s) -
Dank Gillian,
Lucroy Michael D.,
Griffey Stephen M.,
GandourEdwards Regina,
Madewell Bruce R.
Publication year - 2002
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2002.tb02414.x
Subject(s) - medicine , cats
Immunohistochemistry was used to examine feline lymphoid tumors for bcl‐2 and MIB‐1 expression. Tumor tissues from 29 cats were selected to represent 2 groups—cats that did not respond to chemotherapy and cats that responded to therapy. Median bcl‐2 immunoreactivity was 60%, and median MIB‐1 reactivity was 47%. There was no significant difference in median survival time between cats with tumors with high levels of bcl‐2 expression and those with low levels of expression. There was no significant difference in median survival time between cats with tumors with high levels of MIB‐1 expression and those with low levels of expression. Mean bcl‐2 immunoreactivity was significantly ( P = .0004) higher in low‐grade (73.2%) than in high‐grade (16.9%) lymphomas, whereas the mean MIB‐1 immunoreactivity was significantly ( P = .0201) higher in high‐grade (61.2%) lymphomas than in low‐grade (35.0%) lymphomas. The mean bcl‐2 immunoreactivity was significantly ( P = .0042) greater in T‐cell lymphomas (66.8%) than in B‐cell lymphomas (22.8%), whereas the mean MIB‐1 immunoreactivity was significantly ( P = .0052) lower in T‐cell lymphomas (36.4%) than in B‐cell lymphomas (65.2%). Although expression of bcl‐2 and MIB‐1 did not appear to be linked to responses to chemotherapy in cats with lymphoma, the data suggest a possible role for these regulatory proteins in the biology of feline lymphomas.